"If Forest terminates Warner-Lambert's co-promotion agreement because of [a Warner-Lambert] merger, under no circumstances would Forest be obligated to make payments until 2004," Forest Chairman Howard Solomon says in a Jan. 27 letter to "The Pink Sheet." Warner-Lambert told a Jan. 19 teleconference that "even if there is that change of control and they exercise their option, there's a period of step down payments that take place through the balance of the six year agreement" (1"The Pink Sheet" Jan. 24, p. 14). Forest and Warner-Lambert are in discussions to end the co-promotion agreement for the antidepressant
You may also be interested in...
Warner-Lambert's Lipitor is showing no signs of a negative impact from the distractions caused by the hostile takeover bid launched by Warner's marketing partner Pfizer.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials